Long-term Treatment of Insulin-insensitive Mares with Cabergoline: Effects on Prolactin and Melanocyte Stimulating Hormone Responses to Sulpiride and on Indices of Insulin Sensitivity

Valencia, Nicole Arana; Thompson, Donald L.; Oberhaus, E.L.; Gilley, R.M.

doi:10.1016/j.jevs.2013.12.015

Cited by 14 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study treated horses with clinical signs of EMS with 1 mg pergolide/day for 8 weeks and found improved OST results (D. McFarlane, personal communication), although it is difficult to rule out early PPID in those horses with EMS, so additional studies are required to confirm any specific effect of pergolide on ID. Several dopamine agonists improve insulin regulation and suppress insulin concentrations in other species, although no beneficial effect of cabergoline on ID in horses has been found …”

Section: Pharmacologic Aidsmentioning

confidence: 99%

ECEIM consensus statement on equine metabolic syndrome

Durham¹,

Frank

McGowan

et al. 2019

Veterinary Internal Medicne

183

227

View full text Add to dashboard Cite

Equine metabolic syndrome (EMS) is a widely recognized collection of risk factors for endocrinopathic laminitis. The most important of these risk factors is insulin dysregulation (ID). Clinicians and horse owners must recognize the presence of these risk factors so that they can be targeted and controlled to reduce the risk of laminitis attacks. Diagnosis of EMS is based partly on the horse's history and clinical examination findings, and partly on laboratory testing. Several choices of test exist which examine different facets of ID and other related metabolic disturbances. EMS is controlled mainly by dietary strategies and exercise programs that aim to improve insulin regulation and decrease obesity where present. In some cases, pharmacologic aids might be useful. Management of an EMS case is a long‐term strategy requiring diligence and discipline by the horse's carer and support and guidance from their veterinarians.

show abstract

Section: Pharmacologic Aidsmentioning

confidence: 99%

ECEIM consensus statement on equine metabolic syndrome

Durham¹,

Frank

McGowan

et al. 2019

Veterinary Internal Medicne

183

227

View full text Add to dashboard Cite

show abstract

“…In accordance with previous reports ( 10 , 11 , 17 ), horses initially received treatment with ERC as an intramuscular injection (5 mg/mL) 2 at a “high” dose of 0.01 mg/kg (HDERC). Some horses were reported by owners to experience in appetence at this higher dose, and prompting a change in the practice protocol to use a “low” dose of 0.005 mg/kg (LDERC) for subsequent cases in an attempt to mitigate issues with appetite reduction.…”

Section: Methodsmentioning

confidence: 77%

Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction

Sundra,

Kelty,

Rossi

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

IntroductionDopaminergic agonists are accepted as the most effective treatment for pituitary pars intermedia dysfunction. However, some horses are refractory to daily oral pergolide, the recommended registered treatment. Extended-release cabergoline (ERC) injection may offer an alternative. The objective of this retrospective case series was to describe clinical and endocrinological responses to ERC.MethodsMedical records of horses treated with weekly intramuscular injections of ERC (5 mg/mL, BOVA Aus) at either 0.01 mg/kg (high dose, HD) (n = 10) or 0.005 mg/kg (low dose, LD) (n = 30) were reviewed. Short-term ACTH responses were assessed at 5–8 days using a Wilcoxon signed ranked test. Longer-term ACTH responses (30 to 365 days) were assessed using generalised estimating equations.ResultsFive to eight days after the first dose of LDERC, median adrenocorticotropic hormone (ACTH) concentration was lower (p = 0.001), changing from 153 pg/mL (IQR: 78, 331) to 57 pg/mL (IQR: 30, 102). With HDERC, median ACTH concentration was also 153 pg/mL (IQR: 96, 185) before and then 56 pg/mL (IQR: 29, 86) after 5–8 days of treatment (p = 0.047). Over 12 months of treatment, ACTH concentration ranged from 14 to >1,250 pg/mL (median: 51 pg/mL) in horses treated with LDERC and 20 to 472 pg/mL (median: 50 pg/mL) in horses treated with HDERC. Measurements remained above the seasonal reference range in 39.3 and 52.3% of horses treated with LDERC and HDERC, respectively. Clinical improvement was reported by owners in 78.3 and 100% of horses treated with LDERC and HDERC, respectively. Partial, self-limiting inappetence was reported in 30.0% of LDERC and 60% HDERC cases. Seven horses exhibited lethargy (5 LDERC, 2 HDERC). Insulin concentrations measured 30 days post-ERC treatment were no different from baseline.DiscussionClinical and endocrinological responses were consistent with results of previous reports of oral pergolide treatment. Weekly injection of ERC may be an effective alternative to pergolide; the 0.005 mg/kg dose appeared to be as effective, with less risk of inappetence, than the 0.01 mg/kg dose that has been reported previously.

show abstract

“…Data from several studies have shown that treatment with pergolide mesylate and other dopamine agonists results in reduction of plasma concentration of ␣-MSH, ACTH and insulin in horses with PPID Donaldson et al, 2002;Valencia et al, 2014). Anecdotal information also suggests dopamine agonist treatment improves incidence and/or severity of opportunist infections.…”

Section: Discussionmentioning

confidence: 99%